(All times are in Central Standard Time)

Prevention Special Session: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction

Moderator: Carol Fabian, University of Kansas Medical Center, Westwood, Kansas

• Lifestyle, Genetic, and Epigenetic Interactions in Predicting Development of Obesity and Response to Calorie Restriction and Physical Activity
  Catherine Duggan, Fred Hutch Cancer Center, Seattle, Washington
• Achieving Sufficient Fat loss and Metabolic Improvement to Reduce Cancer Risk:
  Newer Generation GLP-1n and GIP Receptor Agonists (NUSH-Based Therapeutics)
  Neil Iyengar, Memorial Sloan Kettering Cancer Center
• Impact and Types of Exercise and Pharmacotherapy in Weight Loss 
  John Jakicic, University of Kansas Medical Center, Westwood, Kansas
• Panel Discussion

Career Development: Navigating the Road to Success – Early Funding for Research and Beyond     

Moderator: Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona

• Federal Funding Opportunities
  Oliver Bogler, National Cancer Institute, Bethesda, Maryland
• Foundation Funding
  Sara Tolaney, Daba-Farber Cancer Institute, Boston, Massachusetts
• Interactions with Industry
  Minetta Liu, Natera, Austin, Texas
• Panel Discussion

Special Session 3: Sex, Drugs, Rock and Roll

Moderator: Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York
Patient Advocate: Tomika Bryant, King of Prussia, Pennsylvania

• Supplements and Cannabis
  Heather Greenlee, Fred Hutch Cancer Center, Seattle, Washington
• Sexual Health
  Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island
• Exercise During Treatment 
  Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York
• Alcohol
  Marilyn Kwan, Kaiser Permanente Northern California, Pleasanton, California
• Panel Discussion

2:00 – 3:45 pm
 

Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials

Moderator: Christine Desmedt, KU Leuven, Leuven, Belgium

• Multiplex Imaging for Precision Oncology
  Raza Ali, Cancer Research UK, Cambridge, United Kingdom
• Single Cell T-Cell Receptors and B-Cell Receptors 
  Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium
• Spatial Transcriptomics
  Christos Sotiriou, Institut Jules Bordet, Brussels, Belgium
• Cancer Immunology Discovery Approaches into Clinical Trials
  Emanuela Romano, Institut Curie, Paris, France
• Panel Discussion

4:00 – 5:45 pm
 

Educational Session 1: Mind the Gap — Breast Cancer in the Young

Moderator: Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Patient Advocate: Na'Diah Smith, Dallas, Texas

• Biology of Breast Cancer in Young Women
  Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
• Ovarian Suppression - Who, When, Why, and for How Long 
  Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia
• Survivorship
  Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland
• Panel Discussion

4:00 – 5:45 pm
 

Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment

Moderator: Moderator: Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania
Patient Advocate: Ellen Landsberger, New York City

• Review of Current Technologies
  Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts
• Early Detection and Molecular Recurrent Disease 
  Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee
• Utility in the Metastatic Setting
  David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada
• Panel Discussion

4:00 – 5:45 pm

Educational Session 3: Tumor Heterogeneity and Evolution

Moderator: Reuben S. Harris, UT Health San Antonio, San Antonio, Texas

• Therapy Induced Evolution
  Nicholas Navin, UT MD Anderson Cancer Center, Houston, Texas
• Genomic and Microenvironment Determinants of Breast Cancer Progression
  Christina Curtis, Stanford University, Stanford, California
• Single Cell Genomics in Triple Negative Breast Cancer
  Ashley Laughney, Weill Cornell Medicine, New York, New York
• Panel Discussion

4:00 – 5:45 pm

Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment 

Moderator: Javier Cortes, International Breast Cancer Center, Barcelona, Spain

Patient Advocate: Thelma Brown, Birmingham, Alabama

• Neoadjuvant Management and Adaptive Strategies
  Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
• Treatment of Small Tumors in Early-Stage Setting
  Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
• Post Neoadjuvant Management for non pCR 
  Joyce O'Shaughnessy, Baylor Charles A. Sammons Cancer Center, Dallas, Texas
• Panel Discussion

(All times are in CST)

Keynote Address

Dr. William Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts

Early Detection

Moderator: Ismail Jatoi, UT Health San Antonio Mays Cancer Center, San Antonio, Texas

• Risk-Based Screening in the Average Population
  Karla Kerlikowske, University of California San Francisco, San Francisco, California
• Novel Imaging Modalities 
  Connie Lehman, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts
• Screening for High-Risk Women
  Speaker to be announced
• Panel Discussion

Clinical Case Discussions

Moderator: Debra Patt, Texas Oncology, Austin, Texas
Patient Adovcate: Kelly Shanahan, Tahoe, California

• Sonya Reid, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
• Icro Meattini, Florence University Hospital, Florence, Italy
• Tari King, Dana-Farber Cancer Institute, Boston, Massachusetts
• Joannie Ivory, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
• Anne Salomon, Institut Curie, Paris, France
• Harold Burstein, Dana-Farber Cancer Institute, Boston, Massachusetts

State of the Art Session 1: The Winding Road of Immune Biomarkers in Early Breast Cancer

Moderator: Sherene Loi, Peter MacCallum Cancer Centre, Melbourne, Australia

• TILs: An Update After 10 Years of Research
  Roberto Salgado, Peter MacCallum Cancer Centre, Melbourne, Australia
• Immune Biomarkers Beyond TILs 
  Justin Balko, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
• Deploying Immune Biomarkers in Clinical Trials
  Priyanka Sharma, University of Kansas Medical Center, Westwood, Kansas
• Panel Discussion

Clinical Controversies: Omission of Axillary Staging in ER Positive Breast Cancer: Implications on Adjuvant Therapies

Moderator: Monica Morrow, Memorial Sloan Kettering Cancer Center, New York City

• Omission of Axillary Staging in ER+ Disease What is The Data?
  Elizabeth Mittendorf, Dana-Farber Cancer Institute, Boston, Massachusetts
• Omission of Axillary Staging in ER+ Disease Implications for Radiotherapy
  Speaker to be announced
• Omission of Axillary Staging in ER+ Disease: Implications for Adjuvant Systemic Therapy
  Kevin Kalinsky, Emory Winship Cancer Institute, Atlanta, Georgia
• Radiation Post pCR
  Richard Zellars, Indiana University School of Medicine, Indianapolis, Indiana
• Panel Discussion

3:30 – 5:15 pm

Educational Session 5: Unlocking New Targets with Molecular Degraders

Moderator: Carlos Areraga, UT Southwestern Medical Center, Dallas, Texas

• PROTACs
  Speaker to be announced
• Lysosome-targeting Chimeras
  Speaker to be announced
• Biparatropic Antibodies
  Speaker to be announced
• Panel Discussion

Educational Session 6: Case Based Clinical Approach to ER Positive Metastatic Breast Cancer

Moderator: Sara Hurvitz, Fred Hutch Cancer Center, Seattle, Washington
Case Presentations and Discussants:
Michael Oliphant, Harvard Medical School, Boston, Massachusetts
Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California
Neil Vasan, Columbia University Irving Medical Center, New York, New York
Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Amy Beumer, Patient Advocate, Mason, Ohio

• Case 1: New diagnosis ER+HER2-MBC: genomic considerations
• Case 2: Can we delay CDK4/6i treatment until the second line?
• Case 3:Selecting therapy after progression of disease on CDK4/6i therapy in patients with PI3K pathway mutations
• Case 4: Selecting treatment for patient with tumor ESR1 mutation
• Case 5: When it's time to move on from endocrine approaches, chemo or ADC?

Educational Session 8: Optimizing Local Therapy

Moderator: Tari King, Dana-Farber Brigham Cancer Center, Boston, Massachusetts
Patient Advocate: Yvonne Florance, Philadelphia, Pennsylvania

• Let’s Talk About PBI
  Atif Khan, Memorial Sloan Kettering Cancer Center, New York, New York
• Axillary Management: When to Dissect and When to Radiate 
  Stephanie Wong, Jewish General Hospital Segal Cancer Centre, McGill University Medical School, Montreal, Canada
• Surgical Prevention and Management of Lymphedema
  Sarah McLaughlin, Mayo Clinic, Jacksonville, Florida
• Panel Discussion 

Poster Session 2
Halls 2-3

(All times are in CST)

Plenary Lecture

The Grand Challenge of Unraveling Social vs Biological Drivers of Racial Disparities in Cancer Outcomes
Melissa B. Davis, Morehouse School of Medicine, Atlanta, Georgia

Poster Session 3
Halls 2-3

The Future of Cancer Genetics Is Here

Moderator: Claudine Isaaks, Georgetown University, Washington, DC
Patient Advocate: Tanja Spanic, Europa Donna Slovenia, Ljubljana, Slovenia

• Saturation Genome Editing-Based Functional and Clinical Classification of VUS in BRCA2
  Fergus Couch, Mayo Clinic, Rochester, Minnesota
• Updates on Risk Prediction Models
  Antonis Antoniou, Cancer Research UK Cambridge Center, Cambridge, United Kingdom
• Reversion Mutations in BRCA1/2 in Response to Therapy 
  Katherine Nathanson, University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania
• Panel Discussion

Molecular Tumor Board

• Dara Aisner, University of Colorado Medical School, Aurora, Colorado
• Jorge Reis-Filho, AstraZeneca, Gaithersburg, Maryland
• Philippe Bedard, Princess Margaret Cancer Centre, Toronto, Canada
• Jenna Canzoniero, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, Maryland
• Bob Riter, Cornell University, Ithaca, New York

• How to Define Triple Negative Breast Cancer
  Rebecca Dent, National Cancer Center Singapore, Singapore
  Charles Perou, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
• Tumor Agnostic Drug Development
  Funda Meric-Bernstam, MD Anderson Cancer Center, Houston, Texas
  Fabrice Andre, Institut Gustave Roussy, Villejuif, France

State of the Art: Revolutionizing Diagnosis and Discovery with Artificial Intelligence 

Moderator: Fred Howard, University of Chicago, Chicago, Illinois

• Pathology
  Speaker to be announced
• Imaging and Screening
  Ritse Mann, Netherlands Cancer Institute, Amsterdam, Netherlands
• Drug Discovery, Deep Learning, and Large Data Management 
  Speaker to be announced
• Panel Discussion

Educational Session 9: Artificial Intelligence in the Clinic

Moderator: Debra Patt, Texas Oncology-Austin Central, Austin, Texas
Patient Advocate: Kay Firth-Butterfield, Austin, Texas

• Hazards and Opportunities
  Andrew Hantel, Dana-Faber Cancer Institute, Boston, Massachusetts
• Beyond Chat GPT: Generative AI in Healthcare 
  Ian Maurer, Genomoncology, Cleveland, Ohio
• Digital Tools for Clinical Practice
  Emily Ray, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
• Panel Discussion

Educational Session 10: Immunotherapy

Moderator: Heather McArthur, UT Southwestern Medical Center, Dallas, Texas

• Immunotherapy in Early ER Positive Breast Cancer 
  Cesar Santa Maria, John Hopkins Medicine, Baltimore, Maryland
• Optimization of Treatment in TNBC
  Marleen Kok, Netherlands Cancer Institute, Amsterdam, Netherlands
• The Future of Immunotherapy 
  Evanthia Roussos Torres, University of Southern California, Los Angeles, California
• Panel Discussion

Educational Session 11: Mind the Gap—Breast Cancer in Older Adults

Moderator to be announced
Patient Advocate: Sandi Stanford, San Antonio, Texas

• The Aging Immune System with Hormonal Changes 
  Speaker to be announced
• Defining and Avoiding Low Value Surgical Therapy 
  Christina Minami, Brigham and Women's Hospital, New York City
• Systemic Therapies
  Hans Wildiers, University Hospital Leuven, Leuven, Belgium
• Panel Discussion

Educational Session 12: The Biology and Treatment Implications of Organ Specific Metastases

Moderator: Heide Ford, University of Colorado Denver School of Medicine, Denver, Colorado
Patient Advocate: Christine Hodgdon, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

• Brain Metastases
  Diana Cittelly, University of Colorado Anschutz Medical Campus, Aurora, Colorado
• Liver Metastases 
  Peter Vermeulen, GZA Hospital Sint-Augustinus, Antwerp, Belgium
• Bone Metastases
  Rachelle Johnson, Vanderbilt University Medical Center, Nashville Tennessee
• Panel Discussion

(All times are in CST)

Concurrent Poster Spotlight Sessions 11-15

Plenary Lecture

Cell Atlases as Roadmaps in Cancer Immunology
Walid Khaled, University of Cambridge, Cambridge, United Kingdom

Poster Session 5
Halls 2-3

New Directions in Breast Cancer Prevention

Moderator: Gretchen Gierach, National Cancer Institute, Bethesda, Maryland

• Prevention Vaccines: Where Are We Now and Where Are We Going?
  Olivera Finn, University of Pittsburgh, Pittsburgh, Pennsylvania
• Can We Use Biomarkers to Implement Prevention?
  Seema Khan, Feinberg School of Medicine of Northwestern University, Chicago, Illinois
• From Bench to Clinical Trial: A New Target for Breast Cancer Prevention 
  Geoff Lindeman, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
• Panel Discussion

Debate: All Patients Should be Offered Universal Germline Genetic Testing

Moderator: Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

• Opening Remarks and Polling
• Debate For
  Allison Kurian, Stanford University, Stanford, California
• Debate Against
  Raymond Kim, UHN Princess Margaret Cancer Centre, Toronto, Canada
• Closing Remarks and Polling

Year in Review

Moderators: Carlos Arteaga, UT Southwestern Medical Center, Dallas, Texas; and Virginia Kaklamani, UT Health San Antonio, San Antonio, Texas

• Translational Science Updates 
  Pedram Razavi, Memorial Sloan Kettering Cancer Center, New York, New York
• Early Breast Cancer Updates 
  Speaker to be announced
• Advanced Breast Cancer Updates 
  Michael Danso, Virginia Oncology Associates, Norfolk, Virginia
• Basic Science
  Neil Vasan, Columbia University, New York, New York